Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith T Flaherty

Showing results (91-100 of 418) with videos related to

Pageof 42
Sort By:
The Lancet. Oncology|February 23, 2010
Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient careDebashish Bose, Funda Meric-Bernstam, Wayne Hofstetter, et al.
Journal of the National Cancer Institute|February 11, 2014
Genetic alterations and personalized medicine in melanoma: progress and future prospectsKlaus G Griewank, Richard A Scolyer, John F Thompson, et al.
Cancer Chemotherapy and Pharmacology|May 8, 2004
A phase I, dose escalation trial of ZD0473, a novel platinum analogue, in combination with gemcitabineKeith T Flaherty, James P Stevenson, Maryann Redlinger, et al.
The Journal of Investigative Dermatology|August 25, 2015
BRAF Inhibition Generates a Host-Tumor Niche that Mediates Therapeutic EscapeInna V Fedorenko, Jennifer A Wargo, Keith T Flaherty, et al.
Molecular Cancer Therapeutics|May 30, 2006
Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastasesKeiran S M Smalley, Nikolas K Haass, Patricia A Brafford, et al.
Cancer Chemotherapy and Pharmacology|February 26, 2011
Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction studyKeith T Flaherty, Chetan Lathia, Reginald F Frye, et al.
Plos One|April 12, 2011
A melanoma molecular disease modelSmruti J Vidwans, Keith T Flaherty, David E Fisher, et al.
Cancer Discovery|July 22, 2021
Rethinking Cancer Clinical Trial Conduct Induced by COVID-19: An Academic Center, Industry, Government, and Regulatory Agency PerspectiveKeith T Flaherty, James H Doroshow, Susan Galbraith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2011
New challenges in endpoints for drug development in advanced melanomaAntoni Ribas, Peter Hersey, Mark R Middleton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2006
Mechanisms of hypertension associated with BAY 43-9006Maria Luisa Veronese, Ari Mosenkis, Keith T Flaherty, et al.
Pageof 42

Showing results (91-100 of 418) with videos related to

Sort By:
Pageof 42
The Lancet. Oncology|February 23, 2010
Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient careDebashish Bose, Funda Meric-Bernstam, Wayne Hofstetter, et al.
Journal of the National Cancer Institute|February 11, 2014
Genetic alterations and personalized medicine in melanoma: progress and future prospectsKlaus G Griewank, Richard A Scolyer, John F Thompson, et al.
Cancer Chemotherapy and Pharmacology|May 8, 2004
A phase I, dose escalation trial of ZD0473, a novel platinum analogue, in combination with gemcitabineKeith T Flaherty, James P Stevenson, Maryann Redlinger, et al.
The Journal of Investigative Dermatology|August 25, 2015
BRAF Inhibition Generates a Host-Tumor Niche that Mediates Therapeutic EscapeInna V Fedorenko, Jennifer A Wargo, Keith T Flaherty, et al.
Molecular Cancer Therapeutics|May 30, 2006
Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastasesKeiran S M Smalley, Nikolas K Haass, Patricia A Brafford, et al.
Cancer Chemotherapy and Pharmacology|February 26, 2011
Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction studyKeith T Flaherty, Chetan Lathia, Reginald F Frye, et al.
Plos One|April 12, 2011
A melanoma molecular disease modelSmruti J Vidwans, Keith T Flaherty, David E Fisher, et al.
Cancer Discovery|July 22, 2021
Rethinking Cancer Clinical Trial Conduct Induced by COVID-19: An Academic Center, Industry, Government, and Regulatory Agency PerspectiveKeith T Flaherty, James H Doroshow, Susan Galbraith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2011
New challenges in endpoints for drug development in advanced melanomaAntoni Ribas, Peter Hersey, Mark R Middleton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2006
Mechanisms of hypertension associated with BAY 43-9006Maria Luisa Veronese, Ari Mosenkis, Keith T Flaherty, et al.
Pageof 42